Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate’s Ability to Block H5N1 Bird Flu Virus

BOSTON, MA, Feb 23, 2026 – (ACN Newswire) – Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of Georgia (UGA) as part of a $100M grant to explore the efficacy of its lead drug candidate in blocking the Highly Pathogenic Avian Influenza (HPAI) H5N1 virus…
Read More